In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease

Schaefer, Saul; Gober, Joel R.; Schwartz, Gregory G.; Twieg, Donald B.; Weiner, Michael W.; Massie, Barry M.

doi:10.1016/0002-9149(90)90331-t

Cited by 88 publications

(47 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, patients with CD without ventricular dysfunction showed, unlike the work done in patients with mild idiopathic dilated cardiomyopathy 25,30,31 , alterations in energy metabolism at rest. Such alterations were less severe than those presented by patients with myocardial dysfunction, but still statistically significant.…”

Section: Ventricular Dysfunction Preserved Ventricular Functioncontrasting

confidence: 53%

“…One of the first clinical studies with phosphorus-31 MRS revealed small alterations in the cardiac energy metabolism of patients with dilated cardiomyopathy 31 . Later, it was demonstrated in 20 patients with dilated cardiomyopathy (9 of ischemic origin and 11 of idiopathic origin), a significant reduction in PCr/b-ATP levels in relation to the control group (PCr/b-ATP of 1.46 ± 0.07 vs dilated cardiomyopathy vs. PCr/ b-ATP of 1.80 ± 0.06 in the control group, p < 0.001) 30 .…”

Section: Ventricular Dysfunction Preserved Ventricular Functionmentioning

confidence: 99%

See 1 more Smart Citation

Avaliação do metabolismo dos fosfatos de alta energia em pacientes com doença de Chagas

Leme¹,

Salemi²,

Parga³

et al. 2010

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

Section: Ventricular Dysfunction Preserved Ventricular Functioncontrasting

confidence: 53%

Section: Ventricular Dysfunction Preserved Ventricular Functionmentioning

confidence: 99%

Avaliação do metabolismo dos fosfatos de alta energia em pacientes com doença de Chagas

Leme¹,

Salemi²,

Parga³

et al. 2010

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…For human 31 P-MRS in heart failure, these results would therefore predict a decrease of the phosphocreatine/ATP ratio. Initial studies, however, failed to detect significant reductions of phosphocreatine/ATP ratios [1,13,34]. These early reports did not grade patients for the severity of heart failure.…”

Section: Heart Failure and Cardiac Transplantationmentioning

confidence: 99%

“…Although reports based on small patient numbers have appeared [34], systematic clinical studies of cardiac energy metabolism in patients with left ventricular hypertrophy due to long-term hypertensive heart disease in relation to left ventricular function, volumes and mass remain to be reported. 31 P-MRS would allow to follow the energetic correlates of hypertrophy regression during various forms of antihypertensive therapy.…”

Section: Abbildungmentioning

confidence: 99%

Cardiac Magnetic Resonance Spectroscopy: Potential Clinical Applications

Neubauer

2000

Herz

View full text Add to dashboard Cite

MR spectroscopy is the only method for non-invasive detection of various aspects of cardiac metabolism in humans. While the 1H nucleus of water and fat molecules is the signal source for MR imaging, the MR spectroscopic technique allows for the study of a number of other nuclei, such as 13C, 19F, 23Na, 31P, 39K and 87Rb. Clinical applications presently are confined to the 31P nucleus. 31P-MR spectroscopy allows the non-invasive study of cardiac high-energy phosphate metabolites ATP and phosphocreatine. The phosphocreatine/ATP ratio is considered an index of the energetic state of the heart. Possible clinical indications include heart failure, valve disease and coronary artery disease. In heart failure, the phosphocreatine/ATP ratio is reduced and correlates with clinical severity, ejection fraction and prognosis. In mitral and aortic valve disease, a reduced phosphocreatine/ATP ratio may indicate the optimum timing for valve replacement. In coronary artery disease, a regional decrease of phosphocreatine during stress ("biochemical ergometry") may indicate local ischemia. Furthermore, absolute quantification of high-energy phosphates may allow diagnosis of myocardial viability. Major technical developments, leading to improved spatial and temporal resolution will be necessary to establish MR spectroscopy as a routine clinical tool.

show abstract

“…3 Clinical studies of LVH using phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) have tended to suffer from small patient numbers and have shown conflicting results. 8,9 Both Conway et al 10 and Neubauer et al 11 while studying patients with aortic stenosis and investigating patients with aortic incompetence, respectively, found that any reduction in the PCr/ATP ratio was related to the degree of heart failure. However, a study of patients with mitral regurgitation found significant reductions in the PCr/ATP ratio that correlated with both the degree of heart failure and LVH.…”

mentioning

confidence: 99%

Myocardial bioenergetic abnormalities in experimental uremia

Chesser

Harwood

Raftery

et al. 2016

IJNRD

View full text Add to dashboard Cite

Purpose: Cardiac bioenergetics are known to be abnormal in experimental uremia as exemplified by a reduced phosphocreatine (PCr)/adenosine triphosphate (ATP) ratio. However, the progression of these bioenergetic changes during the development of uremia still requires further study and was therefore investigated at baseline, 4 weeks and 8 weeks after partial nephrectomy (PNx). Methods: A two-stage PNx uremia model in male Wistar rats was used to explore in vivo cardiac and skeletal muscles' bioenergetic changes over time. High-energy phosphate nucleotides were determined by phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) and capillary zone electrophoresis. Results:31 P-NMR spectroscopy revealed lower PCr/ATP ratios in PNx hearts compared to sham (SH)-operated animals 4 weeks after PNx (median values given ± SD, 0.64±0.16 PNx, 1.13±0.31 SH, P,0.02). However, 8 weeks after PNx, the same ratio was more comparable between the two groups (0.84±0.15 PNx, 1.04±0.44 SH, P= not significant), suggestive of an adaptive mechanism. When 8-week hearts were prestressed with dobutamine, the PCr/ATP ratio was again lower in the PNx group (1.08±0.36 PNx, 1.55±0.38 SH, P,0.02), indicating a reduced energy reserve during the progression of uremic heart disease. 31 P-NMR data were confirmed by capillary zone electrophoresis, and the changes in myocardial bioenergetics were replicated in the skeletal muscle. Conclusion: This study provides evidence of the changes that occur in myocardial energetics in experimental uremia and highlights how skeletal muscle bioenergetics mirror those found in the cardiac tissue and so might potentially serve as a practical surrogate tissue during clinical cardiac NMR investigations.

show abstract

In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease

Cited by 88 publications

References 22 publications

Avaliação do metabolismo dos fosfatos de alta energia em pacientes com doença de Chagas

Avaliação do metabolismo dos fosfatos de alta energia em pacientes com doença de Chagas

Cardiac Magnetic Resonance Spectroscopy: Potential Clinical Applications

Myocardial bioenergetic abnormalities in experimental uremia

Contact Info

Product

Resources

About